Intercept Pharmaceuticals

189 articles with Intercept Pharmaceuticals

• Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease

  10/2/2009

• Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity; Intercept Pharmaceuticals is Advancing the Selective TGR5 Agonist INT-777 to an IND

  9/2/2009

• Nature Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling

  8/7/2008

• Intercept Pharmaceuticals Raises $25 Million Funding

  7/29/2008

• Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer

  1/3/2008

• Intercept Pharmaceuticals Expands Senior Management Team

  5/21/2007

• Intercept Pharmaceuticals Researchers Present Data At DDW Highlighting Role Of FXR In Inflammatory Bowel Disease

  5/24/2006

• Intercept Pharmaceuticals Closes $41 Million Equity Financing; Reports Phase I

  5/16/2006

• Intercept Pharmaceuticals Announces Publication of Study Demonstrating Its Lead Compound Can Reverse Liver Fibrosis

  8/12/2004